Market Overview –
A $8.5 billion Global cell and tissue culture supplies market is expected to be created by 2027.
The global market for Cell and Tissue Culture Supplies, which was previously estimated at US$5.4 billion in 2020 but is now expected to reach US$8.5 billion by 2027, is expected to grow at a CAGR of 6.7% over the analysis period 2020-2027 amid the COVID-19 crisis. The media industry, for example, is expected to grow at a compound annual growth rate (CAGR) of 6.6 percent and generate US$2.8 billion in revenue by the end of the study period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Sera segment is readjusted to a revised 2.2% CAGR for the next 7-year period.
Estimated at $1.5 Billion, the US market is expected to grow by 10.2 percent CAGR over the forecast period.
In 2020, the market for cell and tissue culture supplies in the United States is expected to reach US$1.5 billion. With a projected CAGR of 10.2% from 2020 to 2027, China, the world’s second-largest economy, will have a market worth US$1.9 billion by the year 2027. Japan and Canada, two other notable markets, are expected to grow by 3.6% and 6%, respectively, between 2020 and 2027. Germany is expected to grow at a CAGR of 4.2 percent within Europe. The Reagents Segment is expected to grow at an annual rate of 8%.
COVID-19 impact –
The most recently discovered novel coronavirus, COVID-19, causes an infectious disease. Before its start in Wuhan (China) in December 2019, COVID-19 was largely unknown outside of the region. The COVID-19 pandemic has put a strain on healthcare systems around the world, especially in developing countries. The WHO reports that 271,963,258 confirmed cases of COVID-19 have occurred, with 5,331,019 deaths occurring as a result (as of December 17, 2021). For the most part, deaths occurred in the Americas, Europe and South Asia.
As a result of the COVID-19 pandemic, a number of vaccines and antiviral drugs for this virus have either been approved or are in the process of being developed and manufactured by major pharmaceutical and biotechnology companies. Increasing demand for cell culture products is due to the fact that cell culture is an essential part of drug development and manufacturing.
Humans all over the world are protected against disease thanks to viral vaccines produced in cell culture. The SARS-CoV-2 virus is currently being cultured in mammalian cell lines for research purposes. By using culture media to supply nutrients and component cells, it is possible to produce therapeutics with the desired level of pharmaceutical efficacy under strict environmental control. Researchers can better understand cellular behaviour by using cell culture products like media, reagents, and equipment.
Cell culture technologies are expected to speed up vaccine research and development. Samples of SARS-CoV-2 from patients have been successfully cultured at India’s Centre for Cellular and Molecular Biology (CCMB). Cultured SARS-CoV-2 may be used for a variety of purposes, including the production of vaccines, antibodies or anti-dotes, antibody testing, and drug screening.
Market Dynamics –
New therapies like stem cell and gene therapies are constantly being researched in cell biology. To get reliable results, research tools like reagents and equipment need to be of the highest calibre. The cost of cell biology research has skyrocketed in recent years due to the increasing pressure to meet regulatory guidelines while also maintaining high quality standards (through the use of high-grade products). As a result, small businesses and academic institutions are unable to conduct cell biology research due to a lack of funding. Because of their use in stem cell biology, microcarriers are likely to be a hindrance to the growth of the market. Because microcarriers are attached to cells, harvesting them is required, which adds to downstream processing costs. As a result, the cell culture industry’s expansion is likely to be curtailed.
Scope of the Report –
In its most recent report, Future Market Insights looks at some of the most promising investment opportunities in the global cell culture market. Cell culture market trends, consumer needs and product innovations are all covered in this in-depth analysis of key market dynamics.
The report highlights the most important global cell cultures industry segments and subsegments and provides information on the most important regional pockets, the intensely competitive scenario, the leading product and application segments, the technology landscape, sales and distribution networks, and key industry statistics.
FMI also explains how the future growth of the cell culture market will be bolstered by the increasing popularity of stem cell therapies. It explains in detail the advantages and disadvantages of various cell culture methods. Apart from that, the report discusses how growing drug screening markets affect overall cell culture demand.
Competitive Landscape –
It’s not uncommon for a small number of large corporations to control the majority of the cell culture market share. Various organic and inorganic growth strategies such as partnerships, collaborations, mergers, acquisitions, new product launches and investments in research and development are being used by leading cell culture manufacturers to gain a competitive advantage in the market. As an illustration,
Key Players –
Cell Culture Technologies
GE Healthcare Life Sciences
Irvine Scientific Inc.
Lonza Group AG
Merck Millipore GmbH
MP Biomedicals LLC
Thermo Fischer Scientific Inc.
By Type –
By Applications –
Drug Screening & Development
By Regions –